Back for good

June 2004

RPL is delighted to welcome Clinical Trials Assistant, Bibbi Jilka back to the company after a short spell at Parexel. Bibbi first joined RPL in 2002, having previously worked with Managing Director, Dr Jörg Täubel and Medical Director, Ulrike Lorch at another company. She returned to RPL after just seven months at Parexel.‘I missed RPL's warm friendly environment. It is really exciting to work within a multidisciplinary team with direct access to the Medical Director and the Head Nurse. I am learning all the time and making the most of my training.’In the turn the RPL Directors are pleased to have Bibbi back. Jörg Täubel said, ‘it's very rewarding to hear that RPL offers a stimulating work environment. We want to develop staff to their maximum potential with good training and as much encouragement as possible. We've known Bibbi for a long time and it's great to have her back.’

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more